{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "SVNS.L",
  "generated_at": "2026-01-17T11:51:34.929194Z",
  "top_card": {
    "ticker": "SVNS.L",
    "company_name": "Solvonis Therapeutics plc",
    "sector": "Industrials",
    "market_cap_gbp": 19398249,
    "days_active": 312,
    "apex_score_100": 61,
    "confidence_score_100": 45,
    "ai_final_score_25": 15,
    "ai_strength": "STRONG",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 61/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Solvonis Therapeutics plc",
      "sector": "Industrials",
      "industry": "Specialty Industrial Machinery",
      "exchange": "LSE",
      "market": "MAIN",
      "currency": "GBP",
      "risk_tier": "Low Risk",
      "current_market_cap": 19398249,
      "current_close_price": 0.285
    },
    "basics": {
      "ticker": "SVNS.L",
      "current_price": 0.285,
      "ath": 22.463,
      "atl": 0.1,
      "ath_date": "2022-01-06",
      "atl_date": "2024-03-15",
      "week_52_high": 0.4,
      "week_52_low": 0.11,
      "week_52_high_date": "2025-10-07",
      "week_52_low_date": "2025-04-17",
      "drawdown_from_ath_pct": 98.73,
      "data_start": "2022-01-06",
      "data_end": "2026-01-16",
      "total_bars": 1017
    },
    "latest_signal": {
      "date": "2025-03-10",
      "scan_date": "2026-01-14",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "price": 0.155,
      "drawdown_pct": 88.98,
      "ai_score": 12.0,
      "rsi": 20.0,
      "cycle_position": 0.0505,
      "holding_period_days": 312,
      "current_pnl_pct": 83.87,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -23.08,
      "Rally_Count": 3,
      "days_since_last_high": 7,
      "last_high_date": "2026-01-07",
      "lock_in_reached": true,
      "lock_in_date": "2025-10-07",
      "best_rally_pct": 151.61
    },
    "best_historical_signal": {
      "signal_date": "2024-04-08",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "entry_price": 0.135,
      "peak_price": 1.407,
      "peak_date": "2024-05-31",
      "rally_pct": 942.22,
      "days_to_peak": 53,
      "ai_score": 13.0
    },
    "all_historical_signals": [
      {
        "signal_id": "SVNS.L_2023-07-03",
        "signal_date": "2023-07-03",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.9,
        "current_price": 0.3,
        "current_return_pct": -89.66,
        "best_rally_pct": 3.45,
        "best_rally_date": "2023-07-06",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -90.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 926,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-07-04",
        "signal_date": "2023-07-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.9,
        "current_price": 0.3,
        "current_return_pct": -89.66,
        "best_rally_pct": 3.45,
        "best_rally_date": "2023-07-06",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -90.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 925,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-07-05",
        "signal_date": "2023-07-05",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.8,
        "current_price": 0.3,
        "current_return_pct": -89.29,
        "best_rally_pct": 7.14,
        "best_rally_date": "2023-07-06",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -90.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 924,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-07-06",
        "signal_date": "2023-07-06",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 3.0,
        "current_price": 0.3,
        "current_return_pct": -90.0,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-07-07",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 923,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-07-11",
        "signal_date": "2023-07-11",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.6,
        "current_price": 0.3,
        "current_return_pct": -81.25,
        "best_rally_pct": 81.25,
        "best_rally_date": "2023-07-31",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -89.66,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 918,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-07-12",
        "signal_date": "2023-07-12",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.55,
        "current_price": 0.3,
        "current_return_pct": -80.65,
        "best_rally_pct": 87.1,
        "best_rally_date": "2023-07-31",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -89.66,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 917,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-07-13",
        "signal_date": "2023-07-13",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.9,
        "current_price": 0.3,
        "current_return_pct": -84.21,
        "best_rally_pct": 52.63,
        "best_rally_date": "2023-07-31",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -89.66,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 916,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-07-14",
        "signal_date": "2023-07-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.05,
        "current_price": 0.3,
        "current_return_pct": -85.37,
        "best_rally_pct": 41.46,
        "best_rally_date": "2023-07-31",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -89.66,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 915,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-09-27",
        "signal_date": "2023-09-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 0.3,
        "current_return_pct": -82.35,
        "best_rally_pct": 8.82,
        "best_rally_date": "2023-10-09",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -83.78,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 840,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-09-28",
        "signal_date": "2023-09-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.65,
        "current_price": 0.3,
        "current_return_pct": -81.82,
        "best_rally_pct": 12.12,
        "best_rally_date": "2023-10-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -83.78,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 839,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-01",
        "signal_date": "2023-11-01",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.55,
        "current_price": 0.3,
        "current_return_pct": -80.65,
        "best_rally_pct": -0.0,
        "best_rally_date": "2023-11-02",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 805,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-15",
        "signal_date": "2023-11-15",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.4,
        "current_price": 0.3,
        "current_return_pct": -78.57,
        "best_rally_pct": -0.0,
        "best_rally_date": "2023-11-16",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 791,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-16",
        "signal_date": "2023-11-16",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.4,
        "current_price": 0.3,
        "current_return_pct": -78.57,
        "best_rally_pct": -0.0,
        "best_rally_date": "2023-11-17",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 790,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-17",
        "signal_date": "2023-11-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.4,
        "current_price": 0.3,
        "current_return_pct": -78.57,
        "best_rally_pct": -0.0,
        "best_rally_date": "2023-11-20",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 789,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-22",
        "signal_date": "2023-11-22",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.4,
        "current_price": 0.3,
        "current_return_pct": -78.57,
        "best_rally_pct": -7.14,
        "best_rally_date": "2023-11-23",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 784,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-23",
        "signal_date": "2023-11-23",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.3,
        "current_price": 0.3,
        "current_return_pct": -76.92,
        "best_rally_pct": -3.85,
        "best_rally_date": "2023-11-24",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 783,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-24",
        "signal_date": "2023-11-24",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.25,
        "current_price": 0.3,
        "current_return_pct": -76.0,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-11-27",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 782,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-29",
        "signal_date": "2023-11-29",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.05,
        "current_price": 0.3,
        "current_return_pct": -71.43,
        "best_rally_pct": -0.0,
        "best_rally_date": "2023-11-30",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 777,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-30",
        "signal_date": "2023-11-30",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.05,
        "current_price": 0.3,
        "current_return_pct": -71.43,
        "best_rally_pct": -0.0,
        "best_rally_date": "2023-12-01",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 776,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-12-12",
        "signal_date": "2023-12-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.0,
        "current_price": 0.3,
        "current_return_pct": -70.0,
        "best_rally_pct": 1.0,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 764,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-12-22",
        "signal_date": "2023-12-22",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.725,
        "current_price": 0.3,
        "current_return_pct": -58.62,
        "best_rally_pct": 39.31,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 754,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-12-28",
        "signal_date": "2023-12-28",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.66,
        "current_price": 0.3,
        "current_return_pct": -54.55,
        "best_rally_pct": 53.03,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 748,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-12-29",
        "signal_date": "2023-12-29",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.575,
        "current_price": 0.3,
        "current_return_pct": -47.83,
        "best_rally_pct": 75.65,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 747,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-01-02",
        "signal_date": "2024-01-02",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.575,
        "current_price": 0.3,
        "current_return_pct": -47.83,
        "best_rally_pct": 75.65,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 743,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-01-03",
        "signal_date": "2024-01-03",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.65,
        "current_price": 0.3,
        "current_return_pct": -53.85,
        "best_rally_pct": 55.38,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 742,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-02-23",
        "signal_date": "2024-02-23",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.675,
        "current_price": 0.3,
        "current_return_pct": -55.56,
        "best_rally_pct": 49.63,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 691,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-04",
        "signal_date": "2024-03-04",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.65,
        "current_price": 0.3,
        "current_return_pct": -53.85,
        "best_rally_pct": 55.38,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 681,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-06",
        "signal_date": "2024-03-06",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.525,
        "current_price": 0.3,
        "current_return_pct": -42.86,
        "best_rally_pct": 92.38,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 679,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-08",
        "signal_date": "2024-03-08",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.525,
        "current_price": 0.3,
        "current_return_pct": -42.86,
        "best_rally_pct": 92.38,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 677,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-15",
        "signal_date": "2024-03-15",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.25,
        "current_price": 0.3,
        "current_return_pct": 20.0,
        "best_rally_pct": 304.0,
        "best_rally_date": "2024-05-31",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 670,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-18",
        "signal_date": "2024-03-18",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.275,
        "current_price": 0.3,
        "current_return_pct": 9.09,
        "best_rally_pct": 267.27,
        "best_rally_date": "2024-05-31",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 667,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-04-08",
        "signal_date": "2024-04-08",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.135,
        "current_price": 0.3,
        "current_return_pct": 122.22,
        "best_rally_pct": 648.15,
        "best_rally_date": "2024-05-31",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 646,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-04-09",
        "signal_date": "2024-04-09",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.135,
        "current_price": 0.3,
        "current_return_pct": 122.22,
        "best_rally_pct": 648.15,
        "best_rally_date": "2024-05-31",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -70.3,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 645,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-03",
        "signal_date": "2024-07-03",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.135,
        "current_price": 0.3,
        "current_return_pct": 122.22,
        "best_rally_pct": 188.89,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -23.08,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 560,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-04",
        "signal_date": "2024-07-04",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.135,
        "current_price": 0.3,
        "current_return_pct": 122.22,
        "best_rally_pct": 188.89,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -23.08,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 559,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-05",
        "signal_date": "2024-07-05",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.115,
        "current_price": 0.3,
        "current_return_pct": 160.87,
        "best_rally_pct": 239.13,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -23.08,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 558,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-09",
        "signal_date": "2024-07-09",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.123,
        "current_price": 0.3,
        "current_return_pct": 143.9,
        "best_rally_pct": 217.07,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -23.08,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 554,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-10",
        "signal_date": "2024-07-10",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.143,
        "current_price": 0.3,
        "current_return_pct": 109.79,
        "best_rally_pct": 172.73,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -23.08,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 553,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-11",
        "signal_date": "2024-07-11",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.205,
        "current_price": 0.3,
        "current_return_pct": 46.34,
        "best_rally_pct": 90.24,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -23.08,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 552,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-18",
        "signal_date": "2024-07-18",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.19,
        "current_price": 0.3,
        "current_return_pct": 57.89,
        "best_rally_pct": 105.26,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 6,
        "distance_from_high_pct": -23.08,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 545,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-09-05",
        "signal_date": "2024-09-05",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.153,
        "current_price": 0.3,
        "current_return_pct": 96.08,
        "best_rally_pct": 154.9,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -23.08,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 496,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2025-03-10",
        "signal_date": "2025-03-10",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.155,
        "current_price": 0.3,
        "current_return_pct": 93.55,
        "best_rally_pct": 151.61,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -23.08,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 310,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 42,
      "win_rate_pct": 97.6,
      "avg_rally_pct": 145.03,
      "median_rally_pct": 103.23,
      "best_rally_pct": 942.22,
      "worst_rally_pct": -0.0
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-01-17 01:26:46 UTC",
    "volatility": {
      "atr_normalized": 8.0,
      "stddev_20d": 0.5493
    },
    "trends": {
      "intelligence_signal": "DOWNTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 61/100 indicates strong opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 3 rallies, 152% best run"
    ],
    "main_risk": "Confidence 45/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "SVNS.L",
      "latest": [
        {
          "title": "Holding(s) in Company",
          "announcement_date": "8th Jul 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "8 Jul 2025 07:00\nRNS Number : 0752Q\nSolvonis Therapeutics PLC\n08 July 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BMD1Z199\nIssuer Name\nSOLVONIS THERAPEUTICS PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nOberon Investments Limited\nCity of registered office (if applicable)\nBasildon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n03-Jul-2025\n6. Date on which Issuer notified\n03-Jul-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n2.176000\n0.000000\n2.176000\n128,567,604\nPosition of previous notification (if applicable)\n3.209000\n0.000000\n3.209000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BMD1Z199\n128,567,604\n2.176000\nSub Total 8.A\n128,567,604\n2.176000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n07-Jul-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUBSARVBUBRUR"
        },
        {
          "title": "US Patent allowance for PTSD discovery programme",
          "announcement_date": "7th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "7 Jan 2026 07:00\nRNS Number : 8747N\nSolvonis Therapeutics PLC\n07 January 2026\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nU.S. Patent allowance received for PTSD discovery programme\nDemonstrating scientific and commercial significance\nSolvonis Therapeutics plc (LSE: SVNS\n), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (\"CNS\") disorders, announces that it has received a Notice of Allowance (the \"Allowance\") from the United States Patent and Trademark Office (\"USPTO\") for a series of compounds within its proprietary SVN-SDN-14 Post-Traumatic Stress Disorder (\"PTSD\") discovery programme. One compound from this series is currently being evaluated alongside other candidates, with a lead compound expected to be selected in Q1 2026 in line with prior guidance.\nThe Allowance strengthens the intellectual property foundations of SVN-SDN-14 at an important stage as the programme advances toward lead-candidate selection. In addition to this IP milestone, the Company is highlighting the scientific significance of the newly protected compounds in addressing long-standing challenges in the development of next-generation PTSD therapeutics.\nScientific significance\nSVN-SDN-14 is focused on developing serotonin (\"SERT\"), dopamine (\"DAT\") and noradrenaline (\"NET\") modulators designed to support pro-social engagement and improve the effectiveness of psychological therapy in PTSD.\nWhile balanced modulation of these pathways is increasingly recognised as therapeutically valuable, translating this biology into a practical medicine has historically been difficult. Key challenges have included controlling duration of action,\nmanaging variability between patients, and ensuring compatibility with scalable, real-world clinical use.\nThe newly allowed patent covers a novel chemical series designed to retain the core SERT, DAT and NET activity underpinning the programme, while introducing greater pharmacological control through predictable metabolic deactivation. This approach is intended to maintain therapeutic effects while improving dosing flexibility, safety margins and overall suitability for clinical use.\nIn allowing the claims, the USPTO examiner concluded that no existing patents or publications disclosed or suggested the claimed compounds, confirming the novelty of the approach.\nProfessor David Nutt, Chief Scientific Officer of Solvonis, commented:\n\"These compounds are scientifically exciting because they address a long-standing challenge in this field. They are designed to preserve the monoaminergic profile that supports positive social engagement in therapy, while introducing a level of pharmacokinetic control that has historically been difficult to achieve. This increases our confidence that the core biology of SVN-SDN-14 can be translated into a medicine that is practical to develop, regulate and ultimately deploy.\"\nAnthony Tennyson, Chief Executive Officer of Solvonis, added:\n\"This patent allowance strengthens both the scientific and commercial foundations of our PTSD programme. It reflects our strategy of combining rigorous neuroscience with disciplined medicinal chemistry to build differentiated, scalable CNS therapeutics.\"\nEnquiries:\nSolvonis Therapeutics plc\nVia Walbrook\nAnthony Tennyson, CEO & Executive Director\nSinger Capital Markets\n(Broker)\n+44 (0) 20 7496 3000\nPhil Davies\nWalbrook PR (PR/IR advisers)\nTel: +44 (0)20 7933 8780 or\nsolvonistherapeutics@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nLianne Applegarth\nMob:\n+44 (0)7584 391 303\nRachel Broad\nMob:\u00a0+44 (0)7747 515 393\nAbout Solvonis Therapeutics plc\nSolvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds across addiction, psychiatry, and neurology.\nThe Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional discovery work supporting expansion into broader CNS indications. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.\nIn parallel, Solvonis is advancing proprietary CNS discovery programmes built on a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company's integrated approach to developing therapies across its three strategic pillars.\nWith a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to deliver sustained value through innovation in CNS therapeutics.\nsolvonis.com\n|\nLinkedIn\n|\nX (Twitter)\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCEASFKELSKEFA"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "7th Apr 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "7 Apr 2025 07:00\nRNS Number : 8860D\nSolvonis Therapeutics PLC\n07 April 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BMD1Z199\nIssuer Name\nSolvonis Therapeutics PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of financial instruments\n3. Details of person subject to the notification obligation\nName\nSpreadex LTD\nCity of registered office (if applicable)\nSt. Albans\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n02-Apr-2025\n6. Date on which Issuer notified\n03-Apr-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n5.988900\n1.132400\n7.121300\n163500000\nPosition of previous notification (if applicable)\n6.576900\n0.392000\n6.968900\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BMD1Z199\n137500000\n5.988900\nSub Total 8.A\n137500000\n5.988900%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nCFD/Spread Bet\n26000000\n1.132400\nSub Total 8.B1\n26000000\n1.132400%\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nSam Meisel01727 895138Spreadex is an FCA regulated provider of spread betting and CFD trading. Founded in 1999, Spreadex gives both retail and professional traders the opportunity to trade over 10,000 global markets, including UK small caps. For more information see\nwww.spreadex.com/financials\n.\n12. Date of Completion\n03-Apr-2025\n13. Place Of Completion\nUK\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUNOKRVOUSRAR"
        },
        {
          "title": "Synthesis of development candidate for SVN-SDN-014",
          "announcement_date": "5th Jun 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "5 Jun 2025 07:00\nRNS Number : 5149L\nSolvonis Therapeutics PLC\n05 June 2025\n5 June 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nSynthesis of development candidates for SVN-SDN-014 programme\nFurther to the Company's announcement on 18 March 2025, Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, provides a progress update on its preclinical programme, SVN-SDN-014 (the \"\nProgramme\n\"), a novel series of serotonin (\"\nSERT\n\"), dopamine (\"\nDAT\n\"), and noradrenaline (\"\nNET\n\") modulators in development for trauma-related mental health conditions, including Post-Traumatic Stress Disorder (\"\nPTSD\n\"). Prior to the Company's acquisition of Awakn Life Sciences Corp., which completed on 27 May 2025, the Programme was previously referred to as AWKN-SDN-014.\nThe Programme aims to develop a new class of medicines for PTSD which affects an estimated 13 million adults in the United States alone, with the Company estimating a total affected population of approximately 20 million across the United States, United Kingdom and key other European markets.\nThe SVN-SDN-014 series is designed to enhance pro-social behaviour and is being developed with the aim of delivering an improved safety profile compared to existing investigational treatments for PTSD. By modulating neurochemical pathways associated with trust, empathy, and social bonding, the compounds aim to support patients in rebuilding interpersonal relationships, reducing isolation, and engaging more effectively in therapy.\nThe Company has now completed the synthesis of development candidates, marking the third of seven stages in the SVN-SDN-014 translational development plan. This latest phase involved the synthesis of a focused set of compounds for subsequent preclinical characterisation, including pharmacological and toxicological profiling.\nThe remaining stages for the programme are as follows:\n1. In-vitro screening for SERT, DAT and NET re-absorption inhibition\n2. In-vitro screening for SERT, DAT and NET release - expected to complete by the end of July 2025\n3. Pre-clinical animal testing\n4. Lead candidate selection - expected by the end of Q3 2025\nFurther details of the remaining stages can be found in the Company's announcement on 18 March 2025.\nAnthony Tennyson, Chief Executive Officer of Solvonis, commented:\n\"SVN-SDN-014 represents a novel, mechanism-driven approach to treating PTSD, an area of significant and persistent clinical need. With candidate synthesis now complete, we are progressing the programme toward formal lead selection and IND-enabling studies.\"\nFurther updates will be provided as the Programme advances toward regulatory submission.\nEnquiries:\nSolvonis Therapeutics plc\nAnthony Tennyson, CEO & Executive Directoranthony@solvonis.com\nAllenby Capital Limited\n(Financial Adviser and Joint Broker)Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)Guy McDougall (Sales & Corporate Broking)+44 (0) 20 3328 5656\nSinger Capital Markets\n(Joint Broker)Phil Davies+44 (0) 20 7496 3000\nAbout Solvonis Therapeutics plc\nSolvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds that target high-burden neuropsychiatric conditions with significant unmet need.\nThe Company's lead programs address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 trials for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD program leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.\nWith a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDFIMBTMTMMTIA"
        },
        {
          "title": "Engagement of PharmaVentures",
          "announcement_date": "4th Apr 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "4 Apr 2025 07:00\nRNS Number : 5966D\nSolvonis Therapeutics PLC\n04 April 2025\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n04 April 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nEngagement of PharmaVentures to advise on the commercialisation of late-stage assets being acquired\nSolvonis Therapeutics plc (LSE: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce that it has engaged PharmaVentures Ltd (\"\nPharmaVentures\n\"), a leading global biopharma transaction advisory firm, to support the commercialisation of two clinical-stage programmes, AWKN-001 and AWKN-002. These programmes are being acquired by Solvonis through its proposed acquisition of Awakn Life Sciences Corp. (\"\nAwakn\n\"), which was first announced on 16 December 2024 and is expected to complete in the second quarter of 2025.\nAlcohol Use Disorder\nAWKN-001 and AWKN-002 both target the treatment of Alcohol Use Disorder (\"\nAUD\n\"), a significant unmet medical need that is estimated to affect approximately 10 million people across the UK and major EU markets, and 29 million in the US\n[1]\n. Currently, 90% of patients remain untreated, and the existing treatments and standard of care have relapse rates of up to 75%1.\nPharmaVentures engagement\nThe engagement of PharmaVentures, by the Company, is structured in two phases:\n\u00b7\nPhase 1 - a review of comparable transaction valuations and market sizing exercise in relation to target clinical use of AWKN-001 and AWKN-002; and\n\u00b7\nPhase 2 - transaction advisory support to guide the commercialisation strategy for AWKN-001.\nMarket opportunity for AWKN-001 and AWKN-002\nThe first phase of the engagement - the review of comparable transaction valuations and market sizing exercise in relation to target clinical use of AWKN-001 and AWKN-002 - has now been completed. The analysis by PharmaVentures shows the following:\n\u00b7\nAWKN-001\nis a novel investigational combination therapy for the treatment of severe AUD. It is targeting full mixed marketing authorisation in the UK and EU, with expected regulatory protection to include eight years of data exclusivity in the EU and ten years of concurrent market exclusivity in both regions\nBased on a market analysis by PharmaVentures, comparable transactions for late-stage UK/EU-focused assets in the substance use disorder space, typically achieve a total deal value of approximately \u00a360 million, in upfront and commercial milestone payments, plus additional future material royalties on net sales\n[2]\n.\n\u00b7\nAWKN-002\nis a proprietary, investigational, patent-pending sublingual or buccal esketamine formulation designed for use alongside manualised behavioural therapy in patients with moderate to severe AUD. It is currently in Phase 2b planning in the US and is expected to follow the FDA's 505(b)(2) regulatory pathway.\nAccording to PharmaVentures' market analysis, subject to the successful completion of the planned Phase 2b trial and based on similar transactions for mid-stage assets, comparable assets typically achieve a total deal value of approximately \u00a3150 million, in upfront and commercial milestone payments, plus additional future material royalties on net sales2.\nAdrian Dawkes, Managing Director of PharmaVentures, commented:\n\"Based on market comparables and recent transactions in the substance use disorder space, our analysis highlights the significant commercial potential of these two clinical-stage programmes with potential value based on comparable assets of more than \u00a3200 million as well as future material royalties on net sales. Combined, AWKN-001 and AWKN-002 represent a significant commercial opportunity with potential for significant licensing deals with substantial future royalty streams.\"\nAnthony Tennyson, CEO of Solvonis, added:\n\"We are pleased to be working with PharmaVentures to unlock the full value of these transformative mental health treatments. Completing the market analysis phase marks an important milestone, and we're excited to share these encouraging results. Our mission remains clear: to bring life-changing therapies to patients while creating lasting value for our shareholders.\"\nEnquiries:\nSolvonis Therapeutics plc, Anthony Tennyson, CEO & Executive Director, Email: anthony@solvonis.com\nAllenby Capital Limited (Financial Adviser and Broker) +44 (0) 20 3328 5656\nNick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance) | Guy McDougall (Sales)\nAbout Solvonis Therapeutics plc\nSolvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for mental health disorders. Solvonis' mission is to improve outcomes for individuals suffering from mental health disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the U.S., UK, and key EU markets.\nwww.solvonis.com\n|\nLinkedIn\n|\nX (formerly Twitter)\nAbout PharmaVentures\nPharmaVentures is a transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 30 years, PharmaVentures has acted as advisor on over 1,000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.\nPharmaVentures uses its extensive real world experience coupled with its proven valuation methodologies, commercial insight and data sources to value companies, assets and licensing deals.\nPharmaVentures's valuations are typically used for internal, external and statutory purposes in support of funding rounds, licensing deals, acquisitions and asset sales. PharmaVentures have valued assets across a wide range of different therapy areas such as CNS, Ophthalmology, Oncology, GI and Respiratory diseases.\nAll regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356), and a wholly owned subsidiary of PharmaVentures Ltd.\nhttps://www.pharmaventures.com/\n[1]\n-\nUS Substance Abuse and Mental Health Services (SAMHSA), 2022 National Survey on Drug Use and Health\n-\nNICE - Alcohol-use disorders diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence\n-\nDas DHS Jahrbuch Sucht 2024\n-\nINSERM Collective Expertise Centre. Reducing the harm associated with alcohol consumption [Internet]. Montrouge (FR): EDP Sciences; 2022. PMID: 36576976.\n-\nMonograf\u00eda. Alcohol 2021: Consumo y Consecuencias\n-\nMekonen, T., Chan, G. C. K., Connor, J., Hall, W., Hides, L. and Leung, J. (2021) 'Treatment rates for alcohol use disorders: a systematic review and meta-analysis'\n[2]\nAll contingent elements of any deal are subject to successful completion of clinical development, regulatory approvals and achieving appropriate levels of sales in the market once launched.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDUPUBGCUPAGCW"
        }
      ],
      "themes": [
        "funding",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 125,
      "sentiment_breakdown": {
        "positive": 34.4,
        "neutral": 65.6,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "DOWNTREND"
    },
    "volatility": {
      "atr_normalized": 8.0,
      "stddev_20d": 0.5493
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "catalyst_dates": {
      "proxy_date": "2025-10-07"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "INDUSTRIALS",
      "name": "Industrials",
      "icon": "\ud83c\udfed",
      "color": "#64748b",
      "crash_patterns": [
        "Order book decline or cancellations",
        "Margin compression (input costs)",
        "Cyclical demand weakness",
        "Project delays or overruns",
        "Working capital strain"
      ],
      "recovery_paths": [
        "Order book growth or new contracts",
        "Margin recovery (efficiency gains)",
        "Cyclical upturn (capex recovery)",
        "M&A consolidation",
        "Product innovation or new markets"
      ],
      "active_patterns": [
        "Project delays or overruns"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Order book value (forward revenue)",
        "Book-to-bill ratio",
        "Operating margin trends",
        "Working capital efficiency",
        "Capex cycles (customer industries)"
      ]
    },
    "panic_analysis": {
      "panic_score": 70,
      "signal": "HIGH_PANIC",
      "interpretation": "\ud83d\udfe0 Fear dominant - watch for reversal signs",
      "breakdown": {
        "price_destruction": 40,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": true,
      "opportunity_reason": "\u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 40/40 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 152% proven capacity"
      ],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "HIGH_PANIC",
        "icon": "\ud83d\udfe0",
        "text": "Fear 70/100",
        "color": "#f59e0b"
      },
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 61",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "US Patent allowance for PTSD discovery programme",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Synthesis of development candidate for SVN-SDN-014",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Engagement of PharmaVentures",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "BUY",
      "reason": "\ud83c\udfaf CrashHunter Signal: \u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "70/100",
          "pass": true,
          "icon": "\ud83d\udd34"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "61/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "45/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "1 active",
          "pass": true,
          "icon": "\ud83c\udfed"
        }
      ],
      "pass_rate": "5/5"
    },
    "contrarian_panic": {
      "total_score": 32,
      "band": "\ud83d\udfe2 MILD COMPRESSION (Top 50% - WATCHLIST)",
      "components": {
        "compression": {
          "score": 3,
          "max": 40,
          "signals_30d": 1,
          "signals_60d": 1,
          "signals_90d": 1,
          "signals_per_week": 0.08,
          "total_signals": 42,
          "rsi_extreme_count": 0,
          "rsi_ultra_count": 0,
          "escalation_count": 0,
          "density_score": 3,
          "rsi_score": 0,
          "escalation_score": 0,
          "description": "0.1 signals/week | Early stage"
        },
        "intensification": {
          "score": 10,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM",
            "DEEP CRASH BOTTOM"
          ],
          "escalating": true,
          "sustained": false,
          "current_intensity": 2,
          "pattern": "ESCALATING - Getting worse"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.03,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 14,
          "max": 15,
          "best_historical_rally": 648.2,
          "avg_rally": 101.3,
          "signal_count": 42,
          "description": "BIG POPPER - Historical 5x+ (648%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation"
        }
      },
      "ticker": "SVNS.L",
      "signal_date": "2025-03-10",
      "total_signals_history": 42
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +15 (AI_Technical_Score=12.0/20)",
      "Drawdown reversion potential: +18 (Drawdown_Pct=89.0%)",
      "Volume confirmation: +10 (Relative_Volume=2.0)",
      "Pattern reliability: +10 (Rally_Count=3.0)",
      "Upside history: +8 (best_rally_pct=152%)"
    ],
    "technical_score": {
      "points": 15,
      "ai_score": 12.0,
      "reason": "AI Technical Score 12.0/20 translates to 15/25 points"
    },
    "drawdown_score": {
      "points": 18,
      "drawdown_pct": 88.98,
      "reason": "Drawdown of 89.0% gives 18/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.03,
      "reason": "Relative volume 2.03x gives 10 points"
    },
    "pattern_score": {
      "points": 10,
      "rally_count": 3.0,
      "reason": "3.0 historical rallies gives 10/15 points"
    },
    "upside_score": {
      "points": 8,
      "best_rally_pct": 151.61,
      "reason": "Best rally of 152% gives 8/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=93.5%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2025-03-10"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.62,
    "current_run_pct": 93.55,
    "avg_historical_run_pct": 151.61
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 61/100 APEX score. Historical data shows 3 rallies averaging 152% upside. Current position: +93.5%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 45/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}